Literature DB >> 10397330

Role of DNA aneuploidy, overexpression of p53 gene product, and cellular proliferation in the progression of gastric cancer.

T Sugai1, S Nakamura, N Uesugi, W Habano, T Yoshida, H Tazawa, S Orii, T Suto, C Itoh.   

Abstract

DNA aneuploidy, p53 overexpression, and high cell proliferation frequently occur in gastric cancer. However, little is known about the time of their appearance throughout cancer progression. Therefore, the objective of the present study was to determine when such abnormalities occur during gastric cancer progression. We classified the gastric cancers examined into intestinal (n = 65) and diffuse (n = 34) types. DNA ploidy was examined using flow cytometry and expression of MIB-1 and p53 immunoreactivity were studied using the avidin-biotin complex method in three stages of gastric cancer (mucosal, submucosal, deeply invasive cancer, i.e., advanced cancer). The incidence of DNA aneuploidy in intestinal-type mucosal cancers (15/27, 55.6%) was lower than that of submucosal invasive cancers (14/16, 87.5%) or advanced cancers (19/22, 86.4%), while a low incidence of DNA aneuploidy was observed in each diffuse-type cancer group (mucosal, 1/12, 8.3%; submucosal invasive, 3/9, 33.3%; advanced, 8/14, 57.1%). Although overexpression of the p53 gene in intestinal-type cancer was found in early stage, that in diffuse-type cancer was observed in advanced stage. Among the intestinal-type mucosal cancers, the MIB-1 percent positive was higher in aneuploid tumors than diploid ones. DNA aneuploidy and overexpression of the p53 gene may play an important role in the early tumorigenesis of intestinal-type gastric cancer and in the late event of tumorigenesis of diffuse-type gastric cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10397330     DOI: 10.1002/(sici)1097-0320(19990615)38:3<111::aid-cyto4>3.0.co;2-t

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  4 in total

Review 1.  Clinical aspect and molecular mechanism of DNA aneuploidy in gastric cancers.

Authors:  Eiji Oki; Yuichi Hisamatsu; Koji Ando; Hiroshi Saeki; Yoshihiro Kakeji; Yoshihiko Maehara
Journal:  J Gastroenterol       Date:  2012-03-09       Impact factor: 7.527

2.  Multiple genetic alterations and behavior of cellular biology in gastric cancer and other gastric mucosal lesions:H.pylori infection, histological types and staging.

Authors:  Heng-Jun Gao; Lian-Zhen Yu; Jian-Feng Bai; Yan-Shen Peng; Gu Sun; Han-Lin Zhao; Kun Miu; Xiu-Zhen L ; Xiao-Yong Zhang; Zhi-Quan Zhao
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

3.  MicroRNA-21 inhibits Serpini1, a gene with novel tumour suppressive effects in gastric cancer.

Authors:  Sumitaka Yamanaka; Alexandru V Olaru; Fangmei An; Delgermaa Luvsanjav; Zhe Jin; Rachana Agarwal; Ciprian Tomuleasa; Irinel Popescu; Sorin Alexandrescu; Simona Dima; Mihaela Chivu-Economescu; Elizabeth A Montgomery; Michael Torbenson; Stephen J Meltzer; Florin M Selaru
Journal:  Dig Liver Dis       Date:  2012-03-28       Impact factor: 4.088

4.  Analysis of cell cycle-related proteins in gastric intramucosal differentiated-type cancers based on mucin phenotypes: a novel hypothesis of early gastric carcinogenesis based on mucin phenotype.

Authors:  Tamotsu Sugai; Mitsunori Tsukahara; Masaki Endoh; Yoshihiro Shioi; Noriko Takebe; Yoshiharu Mue; Hiroo Matsushita; Minoru Toyota; Kazuyuki Suzuki
Journal:  BMC Gastroenterol       Date:  2010-06-07       Impact factor: 3.067

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.